PREVACID SOLUTAB Rx
Generic Name and Formulations:
Lansoprazole 15mg, 30mg; e-c del-rel microgranules in orally-disintegrating tabs; strawberry flavor; contains phenylalanine.
Takeda Pharmaceuticals USA, Inc.
Indications for PREVACID SOLUTAB:
Triple therapy (w. amoxicillin + clarithromycin) or dual therapy (w. amoxicillin; use only if allergic, intolerant, or resistant to clarithromycin) for H. pylori eradication in duodenal ulcer disease. Short-term treatment of active duodenal ulcer, active benign gastric ulcer, erosive esophagitis (EE), symptomatic GERD, and NSAID-associated gastric ulcers when NSAID use is continued. To reduce risk of NSAID-associated gastric ulcer in patients with history of gastric ulcer who need an NSAID. Maintenance of healing of duodenal ulcer, EE. Long-term treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome).
Take before eating. Do not crush or chew granules. Caps: swallow whole, or sprinkle granules and mix contents with food or juice (see full labeling) and take immediately. May open caps and mix granules in 40mL apple juice and give via NG tube; flush tube with more juice. SoluTabs: dissolve on tongue; swallow with or without water. May give via oral syringe or NG tube (see full labeling). ≥18yrs: Triple therapy: lansoprazole 30mg + amoxicillin 1g + clarithromycin 500mg, all every 12hrs for 10 or 14 days. Dual therapy: lansoprazole 30mg + amoxicillin 1g, both every 8hrs for 14 days. Duodenal ulcer: 15mg once daily for 4 weeks. Gastric ulcer treatment: 30mg once daily for up to 8 weeks. EE treatment: 30mg once daily for up to 8 weeks; may repeat for 8 more weeks. If relapse occurs, may repeat 8-week course. GERD: 15mg once daily for up to 8 weeks. Maintenance of healing of duodenal ulcer or EE: 15mg once daily. Healing of NSAID-associated gastric ulcer: 30mg once daily for 8 weeks; NSAID ulcer risk reduction: 15mg once daily for up to 12 weeks. Hypersecretory conditions: Initially 60mg once daily, adjust as needed; give daily doses >120mg in divided doses. Severe hepatic impairment: 15mg once daily.
Take before eating. Do not crush or chew granules. Caps: swallow whole, or sprinkle granules and mix contents with food or juice (see full labeling) and take immediately. May open caps and mix granules in 40mL apple juice and give via NG tube; flush tube with more juice. SoluTabs: dissolve on tongue; swallow with or without water. May give via oral syringe or NG tube (see full labeling). GERD or EE: ≤1yr: not recommended. 1–11yrs: ≤30kg: 15mg once daily; >30kg: 30mg once daily. For both: give for up to 12 weeks; doses up to 30mg twice daily have been used. Severe hepatic impairment: 15mg once daily.
Concomitant rilpivirine-containing products.
Symptomatic response does not preclude gastric malignancy. Discontinue if acute interstitial nephritis, cutaneous/systemic lupus erythematosus occurs. Long-term therapy (eg, >3yrs) may lead to malabsorption or deficiency of Vit.B12. Use lowest dose for shortest duration appropriate to condition. Increased risk of osteoporosis-related fractures (hip, wrist or spine) with long-term and multiple daily dose PPI therapy. Monitor magnesium levels with long-term therapy. SoluTabs: phenylketonuria. Severe hepatic impairment: reduce dose. Pregnancy (Cat.B). Nursing mothers: not recommended.
Concomitant St. John's wort, rifampin, atazanavir, nelfinavir: not recommended. May potentiate digoxin, tacrolimus, methotrexate, saquinavir; monitor. Potentiated by voriconazole. May alter absorption of pH-dependent drugs (eg, ketoconazole/itraconazole, iron salts, erlotinib, mycophenolate mofetil, dasatinib, nilotinib). Concomitant digoxin, diuretics may predispose patients to hypomagnesemia. Monitor theophylline, warfarin. Give at least 30 mins before sucralfate. May give antacids concomitantly. May interfere with neuroendocrine tumor diagnostic tests; discontinue lansoprazole at least 14 days prior to CgA level assessment. Interrupt therapy at least 28 days before secretin stimulation test. May cause false (+) urine screening tests for THC.
Proton pump inhibitor.
Diarrhea, abdominal pain, nausea, constipation, headache, bone fracture; rare: hypomagnesemia (w. prolonged PPI therapy); possible C. difficile-associated diarrhea (esp. if hospitalized).
See Amoxil entry for more information on amoxicillin. See Biaxin entry for more information on clarithromycin.
Hepatic. 97% protein bound.
Biliary, renal, fecal.
Caps 15mg—30, 100, 1000; 30mg—100, 1000; SoluTabs—100
Endocrinology Advisor Articles
- Higher BUN May Increase Risk for Incident Diabetes
- Efficacy of Novel GLP-1 Receptor Agonist Drug Device Examined
- Takeout Food May Increase Adverse Health Consequences in Children
- Nonhormonal Options Available for Menopause Symptom Relief
- Plasma Volume Changes Mediate Risk of CV Mortality With Empagliflozin
- New Consensus Recommendations on Use of Continuous Glucose Monitoring
- Does Genetic Susceptibility Lead to Late-Onset Type 1 Diabetes?
- Clinical Outcomes in T2D: Low-Carbohydrate vs Calorie-Restricted Diet
- New Continuous Glucose Monitoring System Now Available for Medicare Patients
- Text Message-Delivered Interventions Effective for Weight Management
- Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D
- Gastric Bypass vs Sleeve Gastrectomy Outcomes in Morbid Obesity
- Acute Kidney Injury Increases Risk for Postdischarge Hypoglycemia in Diabetes
- Novel Deep Learning System May Help Identify Diabetic Retinopathy
- Trends in CVD, Risk Factors, and Medications in Children With T1D